Skip to Main Content

SAN DIEGO — From San Diego to New Jersey, biotechs developing new forms of birth control say they’re doubling down on those efforts after Roe v. Wade was overturned — even as the Supreme Court’s ruling clouded the future of contraception.

Companies are scrambling to accelerate research timelines, pressing insurers to cover approved products, and forging ahead to develop and deliver everything from on-demand, hormone-free female contraception to male birth control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment